House Dems propose $28M to address shortage
WASHINGTON » House Democrats unveiled a $28 million emergency spending bill Tuesday to address the shortage of infant formula in the United States.
Rep. Rosa DeLauro, the Democratic chair of the House Appropriations Committee, said the money would increase Food and Drug Administration staffing to boost inspections of domestic and international suppliers, prevent fraudulent products from getting onto store shelves and acquire better data on the marketplace.
The shortage stems from a February recall by Abbott Nutrition that exacerbated ongoing supply chain disruptions among formula makers, leaving fewer options on stores shelves across much of the country. DeLauro has also been critical of the FDA for a failure to address “with any sense of urgency” the safety concerns at Abbott’s plant in Michigan that prompted the shortage.
The legislation gives Democrats a chance to show they are trying to address a frightening scenario for young families across the country scrambling to ensure they have an adequate supply of food for their babies. Some Republicans have placed responsibility for the shortage squarely on President Joe Biden’s administration while Democrats Tuesday blamed “corporate greed and consolidation.”
“Mothers across the country are looking to us for help and we will not force them to face this crisis on their own,” said House Majority Leader Steny Hoyer, D-Md. “We’re on their side. We’ll see who is on their side when we vote on this legislation.”
Abbott is one of only a handful of companies that produce the vast majority of the U.S. formula supply, so their recall wiped out a large segment of the market. Federal regulators reached a deal this week to allow the company to restart the Michigan plant, but Abbott said it will take eight to ten weeks before new products begin arriving in stores.
The House Appropriations Committee will hear from FDA Commissioner Robert Califf on Thursday to discuss the agency’s budget. Lawmakers are expected to focus much of the discussion on the formula shortage. A panel is also expected to have a second hearing featuring experts who will discuss the recall of infant formula produced at the Abbott facility and the FDA’s handling of the recall.